General informations
          Show the web article Link     Afficher le PDF

Venue: Bordeaux School of Neuroscience

The normal aging process is associated with reduced performance on cognitive tasks that require one to quickly process or transform information to make a decision, including measures of speed of processing, executive cognitive function, working and relational memories. Structural and functional alterations in the brain correlate with these age-related cognitive changes, such as loss of synapses, and dysfunction of neuronal networks. It is crucial to develop new approaches that consider the whole neuroanatomical, endocrine, immunological, vascular and cellular changes impacting on cognition.

This 3-week course will cover the fundamentals of cognitive aging -including inter-individual differences, cognitive and brain reserve and risk factors- and highlight the newest functional imaging methods to study human brain function. The Faculty will share the state-of-the-art molecular, optical, computational, electrophysiological, behavioural and epidemiological approaches available for studying the aging brain in diverse model systems. The Students will learn the potential and limitations of these methods, through practical experience in a combination of lectures addressing aging in both humans and animal models and hands-on-projects. They will acquire sufficient practical experience to model, design and interpret experiments and brainstorm on novel technologies and hypotheses to explore the aging of the brain using more integrative and creative approaches.

Keynote speakers:
Hélène Amieva - University of Bordeaux
Adam Antebi - MPI for Biology of Ageing
Carol Barnes - University of Arizona
LucBuée-Centrede Recherche Jean-Pierre Aubert
Gwenaëlle Catheline - University of Bordeaux
Maria Llorens-Martin - Centro de Biologia
Molecular Severo Ochoa
Aline Marighetto - University of Bordeaux
Lars Nyberg - Umeå University
Laure Rondi-Reig - Sorbonne University
Yaakov Stern - Columbia University
Tony Wyss-Coray - Stanford University

Course director: Luísa Lopes
Co-directors: Cheryl Grady and Nora Abrous

Application deadline: 25 May 2020
Stipends are available

Registration
Fee : 3.500 € (includes tuition fee, accommodation and meals)

The CAJAL programme offers 4 stipends per course (waived registration fee, not including travel expenses). Please apply through the course online application form. In order to identify candidates in real need of a stipend, any grant applicant is encouraged to first request funds from their lab, institution or government.

Kindly note that if you benefited from a Cajal stipend in the past, you are no longer eligible to receive this kind of funding. However other types of funding (such as partial travel grants from sponsors) might be made available after the participants selection process, depending on the course.

For enquiries, please contact: info@cajal-training.org




General informations
18/06/2021
Bordeaux Neurocampus PhD Award Day
      

Save the date!

Bordeaux Neurocampus Doctoral Research Award Day will take place on Friday 18 June.

Meeting Zoom

The list of Neurocentre Magendie PhD students :

Bastien REDON (NCM)
Role of the endocannabinoid system in exercise motivation

Ana DORREGO-RIVAS (NCM)
Revisiting neuronal polarity in the context of PCP

Nadia DI FRANCO (NCM)
CB1 as a potential target for cognitive deficits in Down syndrome

Pierre-Louis RAUX (NCM)
Endogenous regulation of the cannabinoid receptor type 1 (CB1) by the neurosteroid pregnenolone: Characterization of the new CB1-E134G mutant mouse line

Translated with www.DeepL.com/Translator (free version)





Bordeaux, France, June 8th, 2021 – AELIS FARMA (“AELIS”), a biotechnology company specializing in the treatment of brain disorders, today announced a strategic collaboration and option-license agreement with INDIVIOR PLC (LON: INDV) to address the serious consequences of cannabis use disorders (CUD), including cannabis-induced psychosis (CIP).

Dr. Pier Vincenzo Piazza, Co-founder and Chief Executive Officer of AELIS, said: “We are very excited to collaborate with INDIVIOR, whose experience developing approved treatments for addiction and serious mental illnesses will accelerate the development of our new class of therapeutics and the unique approach to cannabis use disorders they provide. This strategic collaboration will enable us to help more patients suffering from cannabis-induced pathologies, which is a large and widely underserved global market. CIP has been identified as the first cause of emergency room (ER) entries for acute psychosis in Europe and, in the U.S., more than 500,000 ER entries per year are due to cannabis use. Further, there are more than 8 million individuals with a diagnosis of CUD in Europe and in the U.S. Because of widespread legalisation of recreational cannabis use, these figures are expected to grow in the upcoming years.”

AELIS’s AEF0117 is the first drug candidate of a new pharmacological class, the Signaling Specific Inhibitors of the CB1 receptor (CB1-SSi), that AELIS developed over the last seven years. AELIS has built extensive knowledge and intellectual property rights around this new family of inhibitors of the CB1 receptors. Thanks to a unique mechanism of action, CB1-SSi selectively inhibit a CB1-mediated hyperactive state, thus preserving the normal functioning of the brain and behaviour.

Under the terms of the agreement with AELIS, INDIVIOR PLC is being granted an option to an exclusive worldwide license for AEF0117 for the treatment of cannabis-related disorders, and in particular, addiction and psychosis. The collaboration will be coordinated by a joint steering committee comprised of drug development leadership from AELIS and INDIVIOR. During the option period AELIS will conduct clinical and non-clinical development to ready AEF0117 to enter Phase 3. If INDIVIOR exercises the option, it would then be responsible for all future development, regulatory, commercial and manufacturing costs and activities.

AELIS will receive an immediate upfront payment of $30 million. Upon successful phase 2b proof of concept studies for cannabis use disorders, INDIVIOR could exercise the option triggering a $100 million license fee payment. AELIS is also eligible to receive additional payments for achieving certain further development and regulatory milestones, as well as mid-teens royalties on any net sales. The phase 2b that will be executed during the option period is a multi-center study evaluating the efficacy of AEF0117 as a treatment of CUD, which will be coordinated by Prof. Frances Levin at Columbia University in the U.S.

AELIS is now broadening its pipeline with a second compound (AEF0217) at the clinical stage, developed as a treatment for cognitive disorders, and several new compounds generated on its proprietary CB1-targeted drug screening platform.

“The collaboration with AELIS is a great opportunity for INDIVIOR. The new pharmacological class developed by the company furthers INDIVIOR’s strategy of targeting innovative treatments for substance use disorders where there is a growing unmet public health need. We look forward to partnering with the AELIS team on AEF0117 in a joint goal to bring the first medication for the treatment of cannabis use disorders to market," said Mark Crossley, INDIVIOR’s Chief Executive Officer.

“We look forward to working with the team at INDIVIOR to bring new treatment options to patients with cannabis-related disorders. We expect that the joint efforts prompted by this agreement will enable INDIVIOR to leverage AELIS’s extensive knowledge of Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), and further accelerate the development of treatment options for a broader range of substance use disorders,” noted Dr. Piazza.




General informations
07/06/2021
10 tips for managing your passwords
    Afficher le PDF

Following World Password Day on 7 May, here are 10 best practices for managing your passwords effectively.

E-mail, social networks, banks, administrations and online businesses, corporate networks and applications... the security of access to all these everyday services is now essentially based on passwords. Faced with the profusion of passwords, the temptation to manage them too simply is strong. Such a practice would be dangerous, as it would considerably increase the risks of compromising the security of your access. Here are 10 good practices to adopt in order to manage your passwords effectively.

Translated with www.DeepL.com/Translator (free version)




General informations
07/06/2021
Agnès Nadjar, laureate 2021 of the Institut Universitaire de France

Congratulations to Agnès Nadjar (Cota team),
laureate 2021 of the Institut Universitaire de France (IUF) in the Junior section. The IUF was created in 1991 with the aim of giving "cognitive oxygen" to the laureate teachers-researchers. Creativity, scientific rigour and interdisciplinary risk-taking form the basis of the selection criteria for joining this prestigious institution.





Expires on 11 June 2021

The Academy of Sciences will award, in 2021, the Lamonica Grand Prize of Neurology of an amount of €110,000.

This annual neurology prize will be awarded to a scientist, without any condition of nationality, working in a French laboratory.

An amount of €10,000 will be awarded to the winner and the remaining €100,000 will contribute to the financing of a post-doctorate.






Bordeaux Neurocampus is a partner of the exhibition "Esprit Critique", presented at Cap Sciences from May 19th to November 14th 2021. Several researchers from our community have participated in the design of "Défi curieux", one of the animations (see below).

Specific events are also planned during the exhibition. More information on these events will be available soon.

More information / booking
https://www.cap-sciences.net/au-programme/exposition/esprit-critique.html

Translated with www.DeepL.com/Translator (free version)




General informations
01/06/2021
Did you know: what quantities of hazardous waste are limits each year by the neurocentre magentie?
    Afficher le PDF

So before throwing, ask yourself.Aurlie offers a small rcapitulative in the seal PDF.





Applications for the Doctoral School competition are open until May 25, 2021, 8:00 am

The competition represents the main admission procedure to the Doctoral School for the preparation of a thesis.

Students must apply online and select two thesis topics from those proposed by the Doctoral School.

At the end of the competition, the highest ranked students receive a ministerial grant, while the others can apply for subjects that are already funded.

For more information / apply

Translated with www.DeepL.com/Translator (free version)